Transgene shares gained ground on the Paris Bourse on Friday, following the company's announcement that it had received authorization to launch a clinical trial in France with its oncolytic virus.

At around 11:20 a.m., the biotech company's shares gained 4.7%, making it one of the biggest gainers on the CAC Mid & Small index, itself up 0.3%.

The company, which develops cancer immunotherapies based on viral vectors, has received authorization from France's Agence nationale de sécurité du médicament et des produits de santé (ANSM) to proceed with a Phase I trial on its proprietary oncolytic virus TG6050.

The drug candidate will be administered intravenously to patients with advanced non-small cell lung cancer (NSCLC).

TG6050 has been designed to express human IL-12, a cytokine known to trigger a powerful immune response, and a full-length anti-CTLA4 antibody.

Its antitumor response combines multiple mechanisms of action by selectively targeting cancer cells and expressing IL-12 and the anti-CTLA4 antibody in the tumor microenvironment.

The trial will include up to 36 patients with advanced-stage NSCLC relapsing after reference therapies, with inclusion of the first patient expected in the first half of 2023.

Copyright (c) 2023 CercleFinance.com. All rights reserved.